MitraClip procedure is an emerging minimally invasive technique for patients with severe mitral regurgitation (MR) who are at high risk for surgery. Transseptal puncture is a key step in MitraClip procedure that is usually performed superiorly and posteriorly in the interatrial septum for optimal MitraClip placement. The presence of interatrial masses such as patent foramen ovale closure device or thrombus makes transeptal puncture more challenging. Safety and efficacy of MitraClip transcatheter mitral valve repair in the presence of intracardiac masses have not been described in the literature. This case describes a 65-year-old woman deemed high-risk for surgery, with symptomatic, severe primary MR and an unusual interatrial mass who underwent a successful MitraClip procedure with the use of three-dimensional (3-D) transesophageal echocardiography (TEE).
INTRODUCTION

M
itraClip procedure is an emerging minimally invasive technique that is safe and well tolerated for patients with severe mitral regurgitation (MR) who are at high risk for surgery. [1, 2] Transseptal puncture represents one of the key steps in MitraClip procedure. In routine practice, optimal puncture site is located superiorly and posteriorly in the interatrial septum. The presence of interatrial masses such as patent foramen ovale (PFO) closure device or a thrombus can make transeptal puncture more challenging. [3, 4] This case describes a patient with symptomatic, severe primary MR deemed high risk for surgical repair, who successfully underwent MitraClip transcatheter mitral valve repair in the setting of an interatrial septal mass.
CASE PRESENTATION
A 65-year-old woman with symptomatic, severe primary MR, who was high risk for surgical repair, was scheduled to undergo a MitraClip transcatheter mitral valve repair. She had favorable mitral valve anatomy [ Figure 1 ]. She had a prior history of bioprosthetic aortic valve replacement for severe aortic stenosis, mitral annular calcification with a mean gradient of 4 mmHg at a heart rate of 56 beats per minute, pulmonary hypertension with an estimated pulmonary artery systolic pressure of 65 mmHg, and normal left and right ventricular function.
Transesophageal echocardiography (TEE) revealed a 2.0 cm × 0.7 cm nonmobile mass present superiorly on the left atrial (LA) side of the interatrial septum [ Figure 2 ]. This was confirmed on three-dimensional (3-D) imaging and color-flow Doppler revealed the absence of an interatrial shunt [ Figure 3 ]. It was recognized that the standard transseptal puncture for MitraClip in the superior aspect of the septum would be challenging in the presence of a closure device, and evidence of thrombus would be a contraindication to MitraClip procedure. Given that there was no clinical suspicion for thromboembolic phenomenon or history of prior transseptal puncture, the mass was most consistent with excess atrial septal tissue in the region of foramen ovale. The decision was made to proceed with MitraClip placement.
LA catheterization under general anesthesia was performed by a careful posterior-inferior transseptal puncture using a BRK-1 Transseptal In routine practice, optimal puncture site is located superiorly and posteriorly in the interatrial septum, approximately 4-5 cm above the mitral annulus, for adequate guide catheter and Mitraclip maneuvering. An enlarged LA may provide adequate depth for this maneuvering despite a relatively inferior transseptal puncture. Although intracardiac thrombus is a contraindication to the procedure, it may be feasible to carefully perform the procedure in the presence of relatively low thromboembolic risk interatrial masses such as interatrial septal aneurysm, lipomatous hypertrophy, or PFO closure devices.
CONCLUSION
In high-surgical-risk patients requiring Mitraclip transcatheter mitral valve repair, it may be feasible to perform the procedure in the presence of relatively low thromboembolic risk interatrial masses such as interatrial septal aneurysm, lipomatous hypertrophy, or PFO closure devices. A detailed assessment of such masses using 3-D TEE, including determining etiology and embolization risk, is key before proceeding with the MitraClip procedure.
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